WELLESLEY, Mass., Nov. 22 /PRNewswire-FirstCall/ -- Coley Pharmaceutical Group, Inc. , today announced that Robert L. Bratzler, Ph.D., President and Chief Executive Officer will present at the upcoming Lazard 2nd Annual Life Sciences Conference in New York, NY on Wednesday, November 30, 2005 at 2:30 p.m. Dr. Bratzler will provide an overview on the Company’s product portfolio and business developments.
Interested parties may access the webcast of the presentation by visiting the Coley Pharmaceutical Group website at http://www.coleypharma.com. A replay of the webcast will be archived on the “Investor Presentations” page in the Investor Center section of the Coley website for two weeks until December 15, 2005.
About Coley Pharmaceutical Group
Coley Pharmaceutical Group, Inc. is an international biopharmaceutical company, headquartered in Wellesley, Massachusetts, USA, that discovers and develops TLR Therapeutics(TM), a new class of investigational drug candidates that direct the human immune system to fight cancers, infectious diseases, asthma and allergy. Coley has established a pipeline of four TLR Therapeutic product candidates currently advancing through clinical development either independently or with partners, and additional product candidates in preclinical development. Coley has product development, research and license agreements with Pfizer, sanofi-aventis, Chiron, GlaxoSmithKline and the United States government.
Coley Pharmaceutical Group, Inc.
CONTACT: Charles H. Abdalian, Jr., Senior Vice President and CFO of ColeyPharmaceutical Group, +1-781-431-9044, cabdalian@coleypharma.com; or KarenL. Bergman, +1-650-575-1509, kbergman@bccpartners.com, or Michelle Corral,+1-415-794-8662, mcorral@bccpartners.com, both of BCC Partners (US)
Web site: http://www.coleypharma.com//
